Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 94.40B P/E 17.12 EPS this Y -6.50% Ern Qtrly Grth -12.90%
Income 5.66B Forward P/E 11.63 EPS next Y 17.00% 50D Avg Chg -2.00%
Sales 27.12B PEG 2.12 EPS past 5Y 1.66% 200D Avg Chg -6.00%
Dividend 4.00% Price/Book 4.50 EPS next 5Y 5.05% 52W High Chg -16.00%
Recommedations 2.50 Quick Ratio 1.15 Shares Outstanding 1.25B 52W Low Chg 25.00%
Insider Own 0.09% ROA 9.78% Shares Float 1.24B Beta 0.20
Inst Own 88.33% ROE 25.54% Shares Shorted/Prior 22.57M/19.67M Price 75.68
Gross Margin 77.80% Profit Margin 20.89% Avg. Volume 5,671,716 Target Price 84.84
Oper. Margin 42.21% Earnings Date Apr 25 Volume 5,249,684 Change 0.00%
About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc. News
04/17/24 GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
04/16/24 Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
04/16/24 Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
04/15/24 Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
04/15/24 GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
04/14/24 GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
04/12/24 Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know
04/10/24 12 Best Depressed Stocks To Buy in 2024
04/09/24 Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
04/09/24 3 Stocks at 52-Week Lows Poised for a Powerful Rebound
04/09/24 11 Best Biotech ETFs To Buy
04/08/24 Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
04/06/24 3 No-Brainer Dividend Stocks to Buy in April
04/05/24 Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
04/03/24 Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
04/02/24 Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
03/28/24 FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
03/28/24 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
03/28/24 Gilead bets on Xilio cancer drug as biotech restructures
03/28/24 7 Value Stocks to Buy at a 52-Week Low in March
GILD Chatroom

User Image Budden Posted - 10 hours ago

$SPY Just noticed Bio has been taking a beating. Sheesh. $GILD with 52 week lows today.. wild

User Image BinaryLogic Posted - 11 hours ago

$GILD I restate my prior position (below). I started at $68.00 and continue to add/scale ahead of earnings next week (4/25). Q1 estimates are a low bar that GILD can beat (IMO). Guidance will be the key here - historical support $60-65, should the Company miss top/bottom line or revise guidance lower. PT ($75-90)

User Image wilno Posted - 16 hours ago

$GILD stronger than bitcoin today. 75 by eoy!

User Image Quantumup Posted - 18 hours ago

BMO Capital $LEGN Outperform/$90: "1Q24 Sales Missed Consensus by ~8%; We Don't see any Long-Term Impact" BMO expects the 2L approval2 sig'ly expand the addressable pop/demand +w/ mfg'g scaling will enable Carvykti sales2meet/beat '24 cons expys (~$1B): $ACLX $jnj $gild $tsvt bmy

User Image DefenseMania Posted - 20 hours ago

$ABBV folks RCUS screaming buy right now , $GILD now owns 33% of the float , purchased their shares at $21.00 for a total of $320 million investment into RCUS I say buyout imminent 2nd 1/2 of 2024 $AMGN $AZN $PFE

User Image Iwillplay Posted - 22 hours ago

$GILD Near 52 week low. Damn.

User Image wealthwithstocks Posted - 23 hours ago

$GILD is getting increasingly attractive. Definitely, high on our list of top value stocks right next to $CSCO. https://app.ziggma.com/securities/GILD#overview

User Image DefenseMania Posted - 2 days ago

$ABBV $GILD $LLY $AMGN a couple months old but definitely an eye opener GILD now has 2 seats on the BOD as I believe AMGN does also ? https://finance.yahoo.com/news/gilead-arcus-announce-amended-collaboration-220000800.html

User Image wilno Posted - 2 days ago

$GILD risk/reward is getting better and better, 75 by eoy!

User Image ANTHONYMOMO Posted - 2 days ago

$HOOK .90 Gilead Sciences (‘Gilead') has purchased 15 million shares of HOOKIPA's common stock for approximately $21.25 million, at a price of $1.4167 per share. BOOM BOOM $GILD

User Image BinaryLogic Posted - 2 days ago

$GILD The SP may fall further to the range of $65-66 ahead of earnings (4/25); however, the setup looks good (IMO) for substantive upside from this level. 25-50% upside from this level (IMO), based on current valuation and anticipated forward earnings growth.

User Image JerryMalone32 Posted - 3 days ago

@novumcarpediem Roche makes all the sense in the world due to the trial design. But I still favor $gild for several reasons. First, it invested in the 2022 PIPE financing. I will always follow the money. Second, it hasn't exercised its option for the HIV vaccine (even though it chose to invest in the PIPE). Those two things are a bit incongruous. I speculate $gild might be acting a bit coy should it want to buy out $grts. Don't forget that beyond the $40 million opt-in for HIV is another 600+ million of milestone payments AND commercial royalties which range from mid-single to low-double-digits. That's a hefty long-term payout to $grts, and it makes sense (if $gild wants to move the asset into ph 2 to consider a buyout. And third, $gild generally seems to be the best fit for $grts combo of oncology and infectious disease assets.

User Image TurtleCapitalManagement Posted - 5 days ago

$GILD setting up nicely for $75 eoy!

User Image wilno Posted - 5 days ago

$GILD awesome! 75 by eoy!

User Image 50bps Posted - 5 days ago

$GILD disgusting

User Image RedBear Posted - 6 days ago

$BMY $pfe $amgn $gild garbage, tiring

User Image bwetz Posted - 6 days ago

$GILD Consolidating before push to $75 EOY

User Image Sober_Loki Posted - 6 days ago

$GILD Added... this is going back to $75

User Image BinaryLogic Posted - 6 days ago

$GILD The Company is clearly undervalued by market or sector to trailing earnings with forward earnings expected to further strengthen the case here for price appreciation. Excellent earnings strength, good liquidity and leverage. 25-50% upside from these levels (IMO), and I am not alone in my expectation.

User Image goodluck2all Posted - 6 days ago

$LPTX when $GILD investing here there’s something look for

User Image maikelm82 Posted - 6 days ago

$LPTX and $ASMB both with $GILD investments and green 🥰

User Image KamiCook Posted - 6 days ago

$GILD classic

User Image DefenseMania Posted - 6 days ago

$GILD will eventually acquire $RCUS imo $PFE $LLY $BMY https://stocktwits.com/DefenseMania/message/568237687

User Image maikelm82 Posted - 6 days ago

$LPTX similar style like $ASMB which also had a big $GILD investment

User Image lidopete Posted - 6 days ago

Raise for $LPTX. $GILD in on (This is a big deal). share price spiked two days ago… someone always knows. + pricing , which comes pre-RCT gastric data, to follow in around June… Show more

User Image RainbowTrump Posted - 1 week ago

$BIIB what do these companies even make money off of? $GILD Anything in the pipeline that’s noteworthy?

User Image BinaryLogic Posted - 1 week ago

$GILD This looks like a rather good value play (IMO) from current levels. [Growth+Income] https://markets.businessinsider.com/news/stocks/three-stocks-at-52-week-lows-poised-for-a-powerful-rebound-1033234600

User Image RedBear Posted - 1 week ago

$GILD long term trash

User Image wilno Posted - 1 week ago

$GILD lower it goes stronger the rally to 75 by eoy.

User Image georgeyann Posted - 1 week ago

$GILD

Analyst Ratings
Wells Fargo Equal-Weight Mar 4, 24
Mizuho Buy Feb 22, 24
Truist Securities Hold Feb 22, 24
RBC Capital Sector Perform Feb 14, 24
Barclays Equal-Weight Feb 12, 24
Oppenheimer Outperform Feb 12, 24
Cantor Fitzgerald Neutral Feb 7, 24
RBC Capital Sector Perform Feb 7, 24
Wells Fargo Equal-Weight Feb 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dickinson Andrew D Chief Financial Offi.. Chief Financial Officer Jan 16 Sell 85.78 5,000 428,900 101,534 01/17/24
Mercier Johanna Chief Commercial Off.. Chief Commercial Officer Jan 09 Sell 85.23 8,242 702,466 82,729 01/10/24
Parsey Merdad Chief Medical Office.. Chief Medical Officer Sep 12 Sell 76.99 1,501 115,562 70,130 09/13/23
Dickinson Andrew D Chief Financial Offi.. Chief Financial Officer Jul 20 Sell 80.00 5,000 400,000 107,587 07/21/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Jun 13 Sell 76.90 1,485 114,197 29,402 06/14/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Mar 13 Sell 78.99 6,126 483,893 70,130 03/14/23
Lofton Kevin E Director Director Mar 09 Option 52.38 8,442 442,192 8,442 03/10/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Mar 01 Sell 79.9619 12,984 1,038,225 70,130 03/02/23
Parsey Merdad Chief Medical Office.. Chief Medical Officer Dec 30 Sell 85.33 553 47,187 45,556 01/03/23
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Nov 01 Option 72.7 16,255 1,181,738 44,588 11/02/22
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Nov 01 Sell 79.25 16,255 1,288,209 28,333 11/02/22
Lofton Kevin E Director Director Apr 28 Option 25.625 16,322 418,251 90,525 04/29/22
Pletcher Brett A EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel Mar 10 Sell 58.24 3,634 211,644 32,576 03/14/22
Pletcher Brett A EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel Feb 09 Sell 63.89 1,691 108,038 32,576 02/11/22
Pletcher Brett A EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel Feb 01 Sell 68.5358 14,061 963,682 32,576 02/02/22
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Aug 18 Sell 72.5 13,610 986,725 20,398 08/18/21
Wilfong Diane E. SVP, Controller & CA.. SVP, Controller & CAO Aug 18 Option 67.56 13,610 919,492 34,008 08/18/21
Whitley Richard James Director Director May 04 Option 20.65 20,282 418,823 51,404 05/04/21